MiNK Therapeutics, Inc. SEC filings INKT
MiNK Therapeutics, Inc. has 265 filings in SEC EDGAR's recent list, going back to Jan 22, 2021. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 13, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Dec 11, 2025 | — |
| CORRESP | Letter to the SEC | Dec 10, 2025 | — |
| EFFECT | Filing | Aug 16, 2024 | — |
| CORRESP | Letter to the SEC | Aug 15, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 15, 2024 | — |
| EFFECT | Filing | Nov 8, 2022 | — |
| CORRESP | Letter to the SEC | Nov 7, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 7, 2022 | — |
| EFFECT | Filing | Oct 14, 2021 | — |
| CERT | Filing | Oct 14, 2021 | — |
| 8-A12B | Filing | Oct 13, 2021 | — |
| CORRESP | Letter to the SEC | Oct 12, 2021 | — |
| CORRESP | Letter to the SEC | Oct 12, 2021 | — |
| CORRESP | Letter to the SEC | Sep 24, 2021 | — |
| CORRESP | Letter to the SEC | Sep 13, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 12, 2021 | — |
| DRSLTR | Filing | Jul 28, 2021 | — |
| DRS/A | Filing | Jul 28, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 1, 2021 | — |
| DRS/A | Filing | Mar 18, 2021 | — |
| DRSLTR | Filing | Mar 17, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 22, 2021 | — |
| DRS | Filing | Jan 22, 2021 | — |
Showing 23 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- INKT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1840229
- Former names
- AgenTus Therapeutics, Inc. (until Mar 18, 2021); AgenTus Therapeutics, Inc. (until Mar 18, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.